Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC
Main Objective:

To evaluate progression-free survival in patients with unresectable renal cell carcinoma (RCC) treated with a combination of gemcitabine, capecitabine, and sorafenib.
Carcinoma, Renal Cell
DRUG: Gemcitabine, Capecitabine and Sorafenib (6 cycles)
Progression-free survival, every 3 cycles and every two months in patients with "sorafenib" administered as monotherapy
security profile, every 3 cycles and every two months in patients with "sorafenib" administered as monotherapy|Objective response index (CR/PR) and tumor growth control (CR/PR/SD), every three cycles and every two months in patients with "Sorafenib" treated as single agent|Duration of response, every three cycles and every two months in patients with "Sorafenib" treated as single agent|Global survival, At last contact date or death date|Time to progression, every three cycles and every two months in patients with "Sorafenib" treated as single agent
Main Objective:

To evaluate progression-free survival in patients with unresectable renal cell carcinoma (RCC) treated with a combination of gemcitabine, capecitabine, and sorafenib.